CC-42344 (Oral PB2 inhibitor)
Influenza A
Key Facts
About Cocrystal Pharma
Cocrystal Pharma is a clinical-stage biotech leveraging a proprietary structure-based drug discovery platform, underpinned by Nobel laureate Dr. Roger Kornberg's expertise, to design novel antiviral therapeutics. Its strategy focuses on targeting highly conserved viral replication enzymes to develop broad-spectrum, resistance-resistant drugs for high-need indications like influenza, coronaviruses, and norovirus. The company has achieved key milestones, including completing a Phase 2a human challenge study for its lead influenza candidate and initiating a Phase 1b study for its dual coronavirus/norovirus protease inhibitor. With a lean operational model and a pipeline spanning early discovery to Phase 2, Cocrystal aims to efficiently advance its candidates toward pivotal trials and partnerships.
View full company profileTherapeutic Areas
Other Influenza A Drugs
| Drug | Company | Phase |
|---|---|---|
| BSV-002 | Kimer Med | Preclinical |
| CC-42344 (Inhaled PB2 inhibitor) | Cocrystal Pharma | Phase 1 |